An in vitro Study: Inhibitory Effect of Carfilzomib on Human Serum Paraoxonase-1 (hPON1)
International Journal of Pharmacology · 15.03.2022 · 18 (3) · 522-526
DOI: 10.3923/ijp.2022.522.526 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Pharmacology, erschienen am 15.03.2022. Verfasst von Hakan Soyut. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben.
Abstract (Originalsprache)
Background and Objective: hPON1 is an HDL-related lactonase that can inhibit LDL. It is considered atheroprotective. hPON1 contributes to the antioxidant function of HDL. It is believed that a decrease in PON1 activity may promote atherosclerosis. This article was aimed to investigate the inhibitory effect of carfilzomib on hPON1. Materials and Methods: In this study, we detect the inhibition between hPON1 and carfilzomib used in the treatment of myeloma.
Results
We determined that carfilzomib showed very strong inhibitory properties for human serum PON1, with an IC50 value of 43.31 mu M and a mean K-i value of 44.37 mu M. We determined that carfilzomib showed competitive inhibition.
Conclusion
The use of carfilzomib, which has a very strong inhibitory effect, in the treatment of multiple myeloma can be very harmful.
Zitieren
APA
Soyut, H. (2022). An in vitro Study: Inhibitory Effect of Carfilzomib on Human Serum Paraoxonase-1 (hPON1). International Journal of Pharmacology, 18(3), 522-526. https://doi.org/10.3923/ijp.2022.522.526
Vancouver
Soyut H. An in vitro Study: Inhibitory Effect of Carfilzomib on Human Serum Paraoxonase-1 (hPON1). International Journal of Pharmacology. 2022;18(3):522-526. doi:10.3923/ijp.2022.522.526
BibTeX
@article{Soyut2022,
author = {Soyut, Hakan},
title = {An in vitro Study: Inhibitory Effect of Carfilzomib on Human Serum Paraoxonase-1 (hPON1)},
journal = {International Journal of Pharmacology},
year = {2022},
volume = {18},
number = {3},
pages = {522--526},
doi = {10.3923/ijp.2022.522.526}
}
EUVIMED